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Interferon regulatory factor 2 (IRF2) is a member of a family of transcriptional factors involved in the modulation
of IFN-induced immune responses to viral infection. To test whether genetic variants in IRF2 predict risk of
atopic dermatitis (AD) and ADEH (atopic dermatitis complicated by eczema herpeticum), we genotyped 78 IRF2
tagging single-nucleotide polymorphisms (SNPs) in both European-American (n¼ 435) and African-American
(n¼ 339) populations. Significant associations were observed between AD and two SNPs (rs793814, P¼ 0.007,
odds ratio (OR)¼ 0.52; rs3756094, P¼ 0.037, OR¼ 0.66) among European Americans and one SNP (rs3775572,
P¼ 0.016, OR¼ 0.46) among African Americans. Significant associations were also observed between ADEH and
five SNPs (P¼ 0.049–0.022) among European Americans. The association with ADEH was further strengthened by
haplotype analyses, wherein a five-SNP (CAGGA) haplotype showed the strongest association with ADEH
(P¼ 0.0008). Eight IRF2 SNPs were significantly associated with IFN-g production after herpes simplex virus (HSV)
stimulation (P¼ 0.048–0.0008), including an AD-associated SNP (rs13139310, P¼ 0.008). Our findings suggest that
distinct markers in IRF2 may be associated with AD and ADEH, which may depend upon ethnic ancestry, and
genetic variants in IRF2 may contribute to an abnormal immune response to HSV.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic skin disease affecting up to
15% of children in industrialized countries (Homey et al.,
2006; Barnes, 2009; Boguniewicz and Leung, 2010). A rare
but serious complication of AD is eczema herpeticum (ADEH).
We have recently reported that AD patients with ADEH have
more severe T helper type 2 (Th2)-polarized disease with
greater allergen sensitization and more commonly have a
history of food allergy, asthma, or both, compared with
patients with AD only (Beck et al., 2009). Although it is well
known that the primary predisposing factor for ADEH is
herpes simplex virus-1 (HSV-1) exposure (Tay et al., 1999; Xu
et al., 2006), genetic susceptibility may be important. Indeed,
our previous studies have demonstrated that a relatively
uncommon null mutation in filaggrin (R501X), a major barrier
protein, was 3 times more prevalent in patients with ADEH
than those AD patients without eczema herpeticum (EH; 24%
vs. 8%, respectively; Gao et al., 2009). In addition, skin
barrier defects due to filaggrin mutations have been shown to
play a crucial role in the development of AD (Nemoto-
Hasebe et al., 2009). However, the disease-associated allele
is only present in 14% of ADEH cases among European
Americans, and was less frequent in non-whites, suggesting
that additional risk variants in filaggrin or others are involved.
Our recent studies found that patients with ADEH have
markedly reduced levels of IFN-g compared with AD patients
without EH, and the reduced IFN-g production may be
because of the IFNG and IFNGR1 single-nucleotide poly-
morphisms (SNPs; Leung et al., 2011). IFN-g is a T helper
type 1 (Th1) cytokine that plays a major role in the host
innate and adaptive immune responses by activating macro-
phages, enhancing natural killer cell activation, promoting
T-cell differentiation, as well as regulating B-cell isotope
switching to IgG2, and is implicated in the pathogenesis of
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allergic diseases (Wild et al., 2000; Gariboldi et al., 2009;
Herberth et al., 2010). Interestingly, infants with reduced
frequencies of IFN-g-producing CD4þ T cells in the cord
blood (first quartile) had a higher risk of developing AD,
suggesting that IFN-g is critical in controlling the develop-
ment of AD.
Interferon regulatory factor 2 (IRF2) is a member of a
family of transcriptional factors involved in the modulation of
cellular responses to IFNs and viral infection (Harada et al.,
1989). IRF2, a transcription repressor (Matsuyama et al.,
1993; Lace et al., 2010), is induced by IFN-g and acts as an
antagonist to IRF1 to block the IFN-g-mediated pathway
(Kroger et al., 2002). IRF2 has been suggested to play a role in
negative control of basophil expansion, which is critical for
the regulation of Th1/Th2 balance (Hida et al., 2005).
Interestingly, Irf2 knockout mice show a defect in Th1 cell
development and spontaneous development of an inflamma-
tory skin disease with histological evidence of epidermal
thickening and keratinocyte proliferation similar to human
AD (Hida et al., 2000). All the studies suggest that IRF2 may
be an important candidate gene for AD and ADEH.
Mutations in the gene encoding IRF2 have been associated
with psoriasis (Foerster et al., 2004b) and AD (Nishio et al.,
2001) in Japanese subjects. However, the Japanese study was
limited to a small number of subjects (N¼24 cases and 24
controls). Rather than replicating the Japanese findings, we
sought to test for associations between IRF2 variants and AD
using a comprehensive tagging SNP approach in ethnically
diverse populations (European Americans and African Amer-
icans) participating in the NIH/NIAID (National Institutes of
Health/National Institute of Allergy and Infectious Diseases)-
sponsored, multicenter Atopic Dermatitis and Vaccinia Net-
work (ADVN), and to explore the potential role of IRF2 in a
more severe form of AD, i.e., ADEH. We further tested for an
association between IRF2 SNPs and IFN-g generation in
mock- or HSV-infected peripheral blood mononuclear cells
(PBMCs).
RESULTS
A total of 78 SNPs were genotyped in IRF2 spanning a 98.7-
kb region on chromosome 4q34.1–q35.1 (Supplementary
Figure S1 online). Genotype frequencies for all SNPs agreed
with expectations under Hardy–Weinberg equilibrium. As
shown in Supplementary Figure S1 online, linkage disequili-
brium (LD) structure differed considerably between the two
ethnic groups, with five LD blocks within IRF2 for the African
Americans and 10 LD blocks for the European Americans
using the criteria of Gabriel et al. (2002).
IRF2 variants are associated with AD in two independent North
American populations
We first tested for association between genetic variants in
IRF2 and diagnosis of AD independently in the European-
American and African-American samples. As summarized in
Table 1, significant associations were observed for IRF2 SNPs
and AD in both European-American and African-American
populations, although for different sets of SNPs (rs13139310,
rs793814, rs12504466, rs3756094 (P¼0.045–0.002), and
rs3775572, rs793794, rs793777, rs6831978 (P¼0.050–0.006),
respectively) in different loci of the IRF2 gene. Two SNPs
remained significant after permutations correcting for multi-
ple testing in the European-American sample (rs793814,
P¼0.007, odds ratio (OR)¼ 0.52, 95% confidence interval
(CI)¼ 0.33–0.80; rs3756094, P¼0.037, OR¼ 0.66, 95%
CI¼0.40–0.94) and one SNP remained significant in the
African-American sample (rs3775572, P¼0.016, OR¼0.46,
95% CI¼0.25–0.83); all three markers were localized to
intron 1. Haplotype analysis failed to identify any enhanced
associations compared with single SNP analysis (Figure 1a).
IRF2 variants are associated with ADEH among European
Americans
We next tested for association between European-American
AD patients with ADEH (N¼ 112) compared with AD
patients without ADEH (N¼166), and observed significant
associations for eight IRF2 SNPs (P-value¼ 0.008–0.043, OR
range¼0.39–2.50, Table 1), with an intronic SNP rs809909
yielding the strongest association (P¼0.008, OR¼0.59, 95%
CI¼0.38–0.90). A synonymous SNP (rs3775543) in exon 9
that was previously associated with type 1 psoriasis (Foerster
et al., 2004a) was significantly associated with an increased
risk of ADEH (P¼0.023, OR¼2.50, 95% CI¼ 1.02–6.11).
After correction for multiple testing, five SNPs remained
significant (rs17488073, rs809909, rs11132242, rs1342852,
and rs1124191, P¼ 0.049–0.022). In a sliding window
haplotype analysis (2–5 SNP windows; Figure 1b), additional
associations were observed, with the strongest signal for a
five-SNP (CAGGA) haplotype spanning a region of 1.1 kb on
chromosome 4q34–35 that included marker rs809909 (minor
allele frequency of 36.7% in ADEHþ and 27.2% in ADEH,
P¼0.0008, Table 2).
IRF2 variants are associated with IFN-c ELISPOT values
To explore the role of IRF2 in regulating IFN-g generation, we
tested for association between the 78 IRF2 SNPs and levels of
IFN-g as determined by spot-forming units in mock- or HSV-
stimulated groups. Within the mock-stimulated group,
association was observed for only one AD-associated SNP
in the full sample (rs12504466, b¼ 0.260, P¼0.015, data
not shown). However, when analyses were restricted to the
HSV-stimulated group, significant associations were observed
for eight SNPs and the enzyme-linked immunosorbent spot
(ELISPOT) values in the full sample (N¼64, P-value range
0.047–0.0008, Table 3), of which SNP rs7677486 showed
the strongest association with lower IFN-g ELISPOT values
after HSV stimulation (b¼0.385, P¼0.0008). Of these,
five SNPs were also associated with IFN-g production among
AD subjects (N¼ 44, P-value range 0.022–0.008). Interest-
ingly, an AD-associated SNP rs13139310 was significantly
associated with reduced levels of IFN-g (GG vs. GAþAA,
b¼0.326, P¼0.008, Figure 2).
Reduced IRF2 expression in ADEH patients
It is possible that a low amount of IFN-g in ADEH patients
may be because of a lower IRF2 expression. To test the
hypothesis, we specifically analyzed the IRF2 expression in
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nonlesional skin biopsies from ADEH, AD patients, and
nonatopic patients in our recent geneChip profiling studies
(Grigoryev et al., 2010). A reduced expression was seen in
skin biopsies from ADEH patients (n¼ 5) compared with
AD patients (n¼11) (ADEH vs. AD, P¼0.048, Figure 3a).
Of interest, the reduced expression in ADEH was further
validated when real-time reverse-transcriptase–PCR was per-
formed in additional sets of skin nonlesional biopsies from
ADEH (n¼8) and AD (n¼ 10) patients (ADEH vs. AD,
P¼0.029, Figure 3b).
DISCUSSION
This study examined genetic variants in IRF2 for association
with AD and its serious clinical complication, i.e., ADEH.
We selected 78 tagging SNPs covering the IRF2 gene and
tested for association in two independent North American
populations. Our data demonstrated significant associations
for IRF2 SNPs and the risk of AD and ADEH in both ethnic
groups. Given the IFN-g generation that we observed was
significantly lower in PBMCs from AD patients, particularly
ADEH patients, compared with nonatopic individuals after
stimulation with HSV ex vivo, we further tested whether these
genetic variants contribute to abnormal IFN-g levels in mock-
and HSV-stimulated PBMCs. Indeed, significant associations
were observed between IRF2 SNPs and IFN-g production in
HSV-stimulated PBMCs from a subset of ADVN subjects.
Overall, our results suggest that genetic variants in IRF2 are
associated with the risk of AD and ADEH, and they may
contribute to an abnormal response to HSV exposure.
In this study, we selected 78 tagging SNPs to provide
comprehensive coverage of the IRF2 gene; among those, four
SNPs are located in the promoter region flanking the SNP
467G/A associated with AD in Japanese families (Nishio
et al., 2001), but none of these were associated with AD
and its associated phenotypes. The exonic SNP rs3775543
(921G/A (Gly/Gly)) that was previously associated with type 1
psoriasis (Foerster et al., 2004b) showed significant associa-
tion with ADEH among European Americans, with an effect
size of 2.50. Because the marker rs3775543 is located at the
þ 3 position of exon 9 and breaks a consensus splicing site
sequence, we speculate that this mutation may lead to the
abolishment of the splicing site, resulting in the intron
remaining in mature mRNA and subsequently producing
aberrant proteins. Indeed, mutations causing incorrect spli-
cing of b-globin mRNA have been shown to be responsible
for some cases of b-thalassemia (Sierakowska et al., 1996).
Additionally, the 921A allele of the exonic SNP rs3775543
was predicted to bind to the serine/arginine-rich family
member ASF/SF2, a pre-mRNA splicing factor playing a role
in mRNA stability (Lemaire et al., 2002; Li and Manley,
Table 1. IRF2 SNPs significantly associated (Po0.05) with AD and ADEH
Minor allele frequency
SNP ID Position Role Risk allele Cases Controls OR (95% CI) P-value Adjusted P-value1
European American (287 AD vs. 157 controls)
rs13139310 185593905 Intron A 0.38 0.48 0.65 (0.42–1.01) 0.045 0.153
rs793814 185591968 Intron T 0.33 0.43 0.52 (0.33–0.80) 0.002 0.007
rs12504466 185590793 Intron G 0.52 0.44 1.36 (1.02–1.83) 0.032 0.054
rs3756094 185587928 Intron A 0.47 0.59 0.66 (0.40–0.94) 0.018 0.037
African American (187 AD vs. 156 controls)
rs3775572 185606446 Intron A 0.41 0.51 0.46 (0.25–0.83) 0.006 0.016
rs793794 185600031 Intron A 0.46 0.59 0.61 (0.39–0.98) 0.030 0.068
rs793777 185551407 Intron G 0.37 0.45 0.74 (0.53–1.02) 0.050 0.161
rs6831978 185540445 Downstream G 0.04 0.09 0.36 (0.11–1.03) 0.035 0.104
European-American population (112 ADEH+ vs. 166 ADEH)
rs7667268 185627070 Intron A 0.75 0.17 0.39 (0.13–1.03) 0.043 0.104
rs807684 185587301 Intron G 0.56 0.40 1.87 (0.99–3.51) 0.037 0.083
rs17488073 185565967 Intron C 0.10 0.18 0.52 (0.27–0.95) 0.025 0.034
rs809909 185561604 Intron A 0.27 0.39 0.59 (0.38–0.90) 0.008 0.022
rs11132242 185558935 Intron G 0.53 0.41 1.60 (0.99–2.60) 0.009 0.049
rs3775543 185547212 Coding exon A 0.18 0.08 2.50 (1.02–6.11) 0.023 0.061
rs1342852 185543111 Downstream A 0.40 0.29 1.62 (1.07–2.44) 0.013 0.043
rs1124191 185539240 Downstream A 0.33 0.50 0.49 (0.27–0.88) 0.010 0.022
Abbreviations: AD, atopic dermatitis; ADEH, atopic dermatitis complicated by eczema herpeticum; CI, confidence interval; IRF2, interferon regulatory factor 2;
OR, odds ratio; SNP, single-nucleotide polymorphism.
1Associations that had a P-value of o0.05 were further adjusted using the PLINK permutation test (10,000 permutations).
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2005), and this binding site was completely abolished in the
921G allele (Foerster et al., 2004b). It would be of interest to
determine whether marker rs3775543 (921G/A) genotypes
contribute to the regulation of IRF2 expression.
We also observed evidence for an association between
other IRF2 SNPs and the risk of ADEH. Haplotype analyses
strengthened the evidence for association with ADEHþ
among European Americans as compared with single marker
analyses. In particular, a five-SNP haplotype C-A-G-G-A
spanning a region of 1.12 kb in intron 6 of IFR2 (rs377552,
rs809909, rs7655371, rs6812958, and rs2797507) showed
the strongest association with the risk of ADEH (ADEHþ
vs. ADEH, 36.7% vs. 27.2%, P¼ 0.0008). Furthermore,
a 7.2-kb region within intron 6 centered on this haplotype
contains three SNPs most strongly associated with ADEHþ
(rs809909, rs11132242, and rs17488073), suggesting that
genetic variants in or around this region may influence
ADEH susceptibility. Replication of these associations was
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Figure 1. Haplotype results for atopic dermatitis (AD) and atopic dermatitis complicated by eczema herpeticum (ADEH). Omnibus P-values constructed
across sliding windows of sizes 2–5 for 78 interferon regulatory factor 2 (IRF2) single-nucleotide polymorphisms (SNPs) and (a) AD and (b) ADEH. Black vertical
lines represent all individual SNP tests, and colored horizontal lines represent 2–5 haplotype tests. *See detailed data in Table 2. Lower plots illustrate
patterns of linkage disequilibrium (LD; D0) in these samples: red squares for strong LD, blue squares for nonsignificant LD, and white squares for little or no LD;
numerical values were generated using HAPLOVIEW software.
Table 2. A five-marker haplotype covering a region of 1.17 kb showed the strongest association with ADEH among
European Americans
rs3775552 rs809909 rs7655371 rs6812958 rs2797507 Frequency
Haplotype C/A A/T G/A G/A C/A ADEH+ ADEH P-value
Haplotype 1 C T G A A 0.313 0.283 0.5099
Haplotype 2 C A G G A 0.102 0.236 0.0008
Haplotype 3 C T A G C 0.367 0.272 0.0397
Haplotype 4 A A G G C 0.054 0.101 0.0967
Haplotype 5 C A G G C 0.088 0.053 0.1503
Haplotype 6 C T G G C 0.075 0.055 0.4230
Omnibus: P=0.0036
Abbreviation: ADEH, atopic dermatitis complicated by eczema herpeticum.
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performed in the smaller subset of African-American ADEH
patients, and significant associations between two SNPs were
observed, which included SNP rs377552, a marker localized
in the same region as the haplotype associated with ADEH
among the European Americans (data not shown). Unfortu-
nately, the modest African-American sample renders these
findings tentative until replication can be performed in a
larger cohort.
Although we observed significant associations with AD in
both ethnic groups, SNPs associated with AD in the European
Americans did not overlap with those associated with AD in
the African Americans. Failure to observe SNP-for-SNP
replication in ethnically diverse populations is not uncom-
mon, and may result primarily from variation in allele
frequencies, population admixture, heterogeneity of the
phenotype, and environmental factors, as we have noted
elsewhere (Mathias et al., 2008). LD structure differed
considerably between the two ethnic groups in this study,
and different sets of tagging SNPs were determined to be
optimal a priori, suggesting genetic heterogeneity. It is likely
that variants other than those tested in this study are true
causal variants, and the markers associated with disease in
this study are presumably in strong LD with the ungenotyped,
‘‘causative’’ SNP(s). We (Mathias et al., 2008) and others
(Neale and Sham, 2004) have suggested that a gene-based
approach, rather than a SNP-for-SNP approach, may provide
evidence for genetic analysis at the functional level. In
addition, to test for the possibility that associations observed
were for manifestations of an HSV exacerbation in ADEH
patients rather than the associated IRF2 SNPs, we performed
association analyses for HSV infection among controls, and
found that none of the ADEH-associated SNPs showed
associations with HSV infection, as defined by both HSV-1
and HSV-2 positivity (data not shown). The findings suggest
that these associations observed for AD and ADEH may be
independent of HSV infection.
A major strength of our study is that we found significant
associations between variants in IRF2 and IFN-g production,
particularly in HSV-stimulated PBMCs. To identify the
possible mechanism, we explored whether genetic variants
in IRF2 contribute to the reduced levels of IFN-g. We
observed significant associations for eight IRF2 SNPs in the
full data set and five SNPs remained significant among AD
patients. Among these, SNP rs13139310, associated with
IFN-g, was also associated with the risk of AD. The results
suggest that these IRF2 SNPs may contribute to a defect in
Th1 cell development by the downregulation of IFN-g
production. Additionally, we demonstrated a reduced IRF2
expression in ADEH patients as compared with AD. These
current results are consistent with findings in the Irf2
knockout mice that showed a defect in Th1 cell development
and spontaneous development of an inflammatory skin
disease (Hida et al., 2000). However, in this study, the
Table 3. Results for the strongest associations of IRF2 SNPs with IFN-c ELISPOT values
All subjects1 AD subjects
dbSNP Position Allele AA AB BB b P-value b P-value
rs11723606 185596272 C/T 348±273 (5) 235±196 (39) 127+85 (18) 0.271 0.027 0.323 0.022
rs13139310 185593905 A/G 129±149 (3) 111±74 (9) 245±192 (44) 0.353 0.007 0.326 0.008
rs1425551 185580052 A/C 129±88 (11) 170±137 (24) 308±219 (22) 0.353 0.001 0.245 0.008
rs7677486 185573846 C/T 125±82 (16) 178±121 (27) 358±173 (18) 0.385 0.0008 0.215 0.022
rs10009261 185570024 C/T 129±108 (5) 142±105 (19) 272±203 (35) 0.307 0.004 0.226 0.020
rs4862365 185548401 C/T NA 291±205 (22) 175±134 (37) 0.218 0.046 0.231 0.092
rs1342852 185543111 C/T 328±293 (7) 245±183 (25) 166±125 (27) 0.212 0.046 0.091 0.421
rs6831978 185540445 A/G 467 (1) 271±226 (13) 198±163 (45) 0.222 0.047 0.250 0.130
Abbreviations: AA, homozygote; AB, heterozygote; AD, atopic dermatitis; BB, wild type; dbSNP, single-nucleotide polymorphism database; ELISPOT,
enzyme-linked immunosorbent spot; IRF2, interferon regulatory factor 2; NA, not applicable; SNP, single-nucleotide polymorphism.
1All subjects are herpes simplex virus (HSV) positive.
IFN-g ELISPOT value was expressed as the mean number of spot-forming units (SFU)±SD per 106 peripheral blood mononuclear cells (PBMCs). The analysis
was performed using a linear regression analysis under a dominant model (AA+AB vs. BB) for a log-transformed and further age- and gender-adjusted SFU.
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Figure 2. Association of interferon regulatory factor 2 (IRF2) single-
nucleotide polymorphism (SNP) rs13139310 with IFN-c production. IFN-g
production was determined by the log10-transformed mean SFU per 10
6 cells
and expressed as spot-forming units (SFU). IRF2 SNP rs13139310 was
significantly associated with herpes simplex virus (HSV)-stimulated IFN-g
levels (GG (n¼44) vs. GAþAA (n¼ 12), P¼ 0.008).
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sample size was relatively modest, and there was a lack of
direct connection between IRF2 SNPs, IRF2 expression, and
IFN-g production, indicating that further studies are clearly
warranted.
We recognize that the associations observed in this study
between the IRF2 SNPs and disease are not particularly
robust, but we contend that the relatively modest P-values are
the result of a limited sample size rather than a type 1 error.
The conventional Bonferroni correction is overly conserva-
tive and may miss real significant functional variants.
Unfortunately, ADEH is a rare disease (B3%); the subjects
used for this study have been recruited after a nearly 5-year
effort from multiple medical centers. Our power calculations
demonstrated that the study population provided sufficient
power (80%) to detect an OR of 2.06, even if the allele
frequency with disease is only 10% (Supplementary Figure S2
online). In addition, although we have attempted to replicate
the findings in the African-American population, the sample
size is too small to make any informative conclusion.
Although our sample size is limited, these findings, besides
our recent report on IFNG and IFNGR1 (Leung et al., 2011),
represent an important contribution to evidence that variants
in IRF2 may confer susceptibility to AD and its most severe
complication, i.e., ADEH. More importantly, no interactions
(gene–gene interaction) were identified between IRF2 and
IFNG and IFNGR SNPs for either AD or ADEH (data not
shown), indicating that the associations we observed for IRF2
are independent of the previous associations with IFNG and
IFNGR1. As a next step, we will identify causal SNPs
centered on the region showing the most significant associa-
tions with ADEH in a relatively large number of subjects with
a comprehensive coverage and determine their functional
relevance to the disease, including associations with IRF2
expression and IFN-g production, and establish their relation-
ships with the risk of ADEH.
Taken together, we have demonstrated evidence for an
association between variants in IRF2 and the risk of AD,
ADEH, and IFN-g production. To our knowledge, this is
previously unreported, and we have provided evidence of
association between ADEH and IFN-g production and genetic
variants in IRF2. Our findings suggest that IRF2 may be a
potential candidate gene and may play an important role in
the pathogenesis of AD and ADEH by altering IFN-g
production.
MATERIALS AND METHODS
Study population and phenotypes
Subjects included 278 unrelated European-American AD patients (of
whom 112 had ADEH) and 157 healthy controls. For replication, we
genotyped the same set of markers on 187 African-American AD
patients (of whom 32 had ADEH), and 156 healthy controls. The
clinical characteristics of ADVN participants have been previously
described (Beck et al., 2009). Briefly, AD was diagnosed using the
US consensus conference criteria (Eichenfield et al., 2003). ADEHþ
was defined as AD patients with at least one EH episode
documented either by an ADVN investigator (or a physician
affiliated with the same academic center) or diagnosis by another
physician and confirmed by HSV PCR, tissue immunofluorescence,
Tzanck smear, and/or culture (Hanifin et al., 2001). Nonatopic,
healthy controls were defined as having no personal history of
chronic disease including atopy. All study participants were further
evaluated by a detailed history and physical examination, as well as
a questionnaire to assess the history of cutaneous viral infections and
concomitant medication use. In accordance with the Declaration of
Helsinki Principles, the study was approved by the institutional
review boards at the National Jewish Health, Johns Hopkins
University School of Medicine, Oregon Health and Science
University, University of California, San Diego, Children’s Hospital
of Boston, and University of Rochester. All subjects gave written
informed consent before participation.
Genotyping and quality control
A total of 78 IRF2 SNPs were genotyped as presented in
Supplementary Table SI online and approaches for SNP selection
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Figure 3. Interferon regulatory factor 2 (IRF2) gene expression was decreased in vaccinia virus (VV)-treated nonlesional skin biopsies from human subjects
with atopic dermatitis complicated by eczema herpeticum (ADEH) compared with subjects with atopic dermatitis (AD). (a) IRF2 expression was detected
by geneChip array in VV-treated nonlesional skin biopsies from ADEH patients (n¼ 5), AD patients (n¼ 11), and nonatopic controls (NA, n¼13). The y axis
represents the fold changes for both AD and ADEH relative to NA. The P-value was determined by comparison made between mean fold changes for
AD and ADEH. (b) IRF2 expression was validated by quantitative real-time reverse-transcriptase–PCR (qRT–PCR) in VV-treated nonlesional skin biopsies
from ADEH (n¼ 8) and AD (n¼ 10) patients. IRF2 expression was normalized to the corresponding glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and expressed as IRF2 mRNA expression relative to GAPDH expression (2DCt).
www.jidonline.org 655
P-S Gao et al.
Genetic Variant in IRF2 and Atopic Dermatitis
are described in the Supplementary Materials online. DNA was
isolated from participants in the ADVN using standard protocols.
IRF2 SNPs were genotyped using a custom-designed Illumina (San
Diego, CA) oligonucleotide pool assay for the BeadXpress Reader
System (Gao et al., 2009). Detailed methods and quality control
have been previously described (Gao et al., 2009).
IFN-c ELISPOT
The differential immune responses (ex vivo) to HSV have been
investigated by measuring IFN-g production in isolated PBMCs from
a subset of the ADVN sample (64 subjects), and clinical character-
istics of participants have been previously described (Leung et al.,
2011). IFN-g production was examined using ELISPOT adapted from
the protocol as previously described (Janetzki et al., 2005). Spot-
forming cells were counted.
Quantitative real-time reverse-transcriptase–PCR
We have recently performed the geneChip profiling analyses in
nonlesional skin biopsies from subjects with ADEH and AD
(Grigoryev et al., 2010). Briefly, skin biopsies from nonlesional
areas were cultured in the presence of media alone (RPMI
supplemented with 10% fetal calf serum) or 2.5 105 p.f.u. vaccinia
virus for 24 hours, and then medium was removed, and biopsy
specimens were submerged in Tri-Reagent (Molecular Research
Center, Cincinnati, OH) for RNA isolation (Howell et al., 2006).
Details on gene expression profiling of sham-treated and vaccinia
virus-treated nonlesional skin biopsied from ADEH patients (n¼ 5),
AD patients (n¼ 11), and nonatopic controls (NA, n¼ 13) have been
previously described (Grigoryev et al., 2010). Among those
differentially expressed genes, IRF2 expression was significantly
downregulated in ADEH when compared with AD. We therefore
validated the IRF2 expression using quantitative real-time reverse-
transcriptase–PCR. The isolated RNA from nonlesional skin biopsies
was used to synthesize complementary DNA and then analyzed
by real-time reverse-transcriptase–PCR using an ABI Prism 7300
sequence detector (Applied Biosystems, Foster City, CA) as
previously described (Gao et al., 2009). IRF2 expressions were
normalized to the corresponding glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and expressed as IRF2 mRNA expression
relative to GAPDH (2DCt). The significance of the differences
obtained was assessed using t-tests in which a P-value ofo0.05 was
considered significant.
Statistical analyses
The Cochran–Armitage trend test was used to test for association
between each individual SNP (under an additive model) and disease
status using PLINK (Gabriel et al., 2002). Haplotype analyses were
performed with PLINK using sliding windows of 2–5 SNPs where
empiric P-values for haplotype frequency differences were generated
over 10,000 permutations. Departures from Hardy–Weinberg equili-
brium at each locus were tested using an w2 test separately for cases
and controls in PLINK (Purcell et al., 2007). Association tests were
performed between individual genetic markers and log-transformed
spot-forming units per 106 PBMCs adjusted for age and gender using
a linear regression analysis under a dominant model. Tests for
association with a P-value of o0.05 were further adjusted by the
PLINK permutation test (10,000 permutations), which provided a
framework for correction for multiple testing (Gabriel et al., 2002).
Power calculation was performed using QUANTO program, version
1.1 (Xu et al., 2006).
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